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a b s t r a c t
Background: Outcomes related to prophylactic catheter ablation (PCA) for ventricular tachycardia
(VT) before implantable cardioverter-deﬁbrillator (ICD) implantation in non-ischemic cardiomyopathy
(NICM) are not well characterized. We assessed the efﬁcacy of single endocardial PCA in NICM
patients.
Methods: We retrospectively analyzed 101 consecutive NICM patients with sustained VT. We compared
clinical outcomes of patients who underwent PCA (ABL group) with those who did not (No ABL group).
Successful PCA was deﬁned as no inducible clinical VT. We also compared the clinical outcomes of
patients with successful PCA (PCA success group) with those of the No ABL group. Endpoints were
appropriate ICD therapy (shock and anti-tachycardia pacing) and the occurrence of electrical storm (ES).
Results: PCA was performed in 42 patients, and it succeeded in 20. The time to ES occurrence was
signiﬁcantly longer in the ABL group than in the No ABL group (p¼0.04). The time to ﬁrst appropriate ICD
therapy and ES occurrence were signiﬁcantly longer in the PCA success group than in the No ABL group
(p¼0.02 and po0.01, respectively).
Conclusion: Single endocardial PCA can decrease ES occurrence in NICM patients. However, high rates of
VT recurrence and low success rates are issues to be resolved; therefore, the efﬁcacy of single endocardial
PCA is currently limited.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V.
1. Introduction
The use of implantable cardioverter-deﬁbrillators (ICDs) is the
gold standard for primary and secondary prevention of sudden
cardiac death [1,2]. However, shocks increase the risk of all-cause
mortality, even if the shocks are inappropriate [3]. Recent studies
have reported the efﬁcacy of prophylactic catheter ablation (PCA)
before ICD implantation in patients with ventricular tachycardia
(VT) and ischemic cardiomyopathy [4–6]. Some studies report the
efﬁcacy of catheter ablation with a combination endocardial and
epicardial approach in patients with non-ischemic cardiomyopa-
thy (NICM) [7,8]. However, the role of PCA before ICD implantation
in NICM patients has not been well described. Results from the few
published studies on the subject vary, but no prospective studies
have compared clinical outcomes of patients with or without
prophylactic endocardial catheter ablation before cardioverter-
deﬁbrillator implantation.
Therefore, this study aimed to compare clinical outcomes of NICM
patients with or without prophylactic endocardial catheter ablation.
Speciﬁcally, we investigated the effect of single endocardial PCA on
the reduction of appropriate ICD therapy and electrical storm (ES).
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2. Material and methods
2.1. Study population
This retrospective analysis included 101 consecutive patients
with sustained VT and NICM who received cardioverter-
deﬁbrillator implantation at either the Hospital of Kobe University
or the Hyogo Brain and Heart Center between January 2005 and
May 2012. NICM included such non-ischemic diseases as idio-
pathic dilated cardiomyopathy (DCM), hypertrophic cardiomyo-
pathy, arrhythmogenic right ventricular cardiomyopathy (ARVC),
cardiac sarcoidosis, valvular heart disease, congenital heart dis-
ease, and others. Patients with polymorphic VT or ventricular
ﬁbrillation (VF) were excluded. Patient selection for PCAwas based
on the physician's discretion, but was primarily chosen for patients
with several sustained episodes of VT admitted in the later years of
the study, when it became a widely accepted therapy. Oral beta-
blockers and/or amiodarone or sotalol were the primary drugs for
chronic management after cardioverter-deﬁbrillator implantation.
2.2. Electrophysiological study and VT ablation
All patients who underwent catheter ablation provided written
informed consent for electrophysiological study and catheter
ablation. Methods for mapping and ablation were identical to
those reported previously [9–11]. Standard multielectrode cathe-
ters were placed in the high right atrium, His-bundle region,
coronary sinus, and right ventricular apex.
Left and/or right ventricular mapping was performed using a
4-mm and/or 8-mm non-irrigated tip or a 3.5-mm irrigated tip
ablation catheter. Initial mapping was performed using the CARTO
system (Biosense Webster, Diamond Bar, CA, USA) or the EnSite
system (EnSite 3000 with Precision Software, Endocardial Solu-
tions, Inc., St. Paul, MN, USA) during sinus rhythm or right
ventricular pacing. A 3-dimensional voltage map of the left
ventricle (LV) and/or right ventricle (RV) was obtained. An area
with low amplitude (o1.5 mV) and fractionated or late potential
was considered an abnormal substrate. Dense scar was identiﬁed
when no local capture on bipolar pacing was observed at 9.9 V and
2-ms pulse width. Pace mapping was used to identify the critical
components of the VT circuit [11].
A programmed stimulation protocol (S1: 600 and 400 ms, with
up to 2 extra stimuli with a minimum 200-ms interval) from the
2 sites (i.e., right/left ventricular apex and right ventricular outﬂow
tract) was performed to induce clinical VT.
Simultaneous recordings of ventricular electrograms (bandpass
ﬁltered 30–500 Hz) and 12-lead surface electrocardiograms (ECGs)
were stored digitally (Prucka Cardiolab, GE Medical Systems,
Milwaukee, WI, USA; Bard LabSystem PRO EP Recording System,
C. R. Bard, Inc. Lowell, MA, USA).
When hemodynamically tolerated VT was induced, VT activa-
tion mapping was performed in the CARTO or EnSite system, and
radiofrequency (RF) current was applied at the central to exit
zones of the circuit as identiﬁed using entrainment pacing during
VT [12,13]. If hemodynamically unstable VT was induced,
substrate-based ablation was performed. RF ablation lesions were
created within the region identiﬁed to be critical for sustaining
clinical VT based on substrate mapping [11]. In cases in which we
could not detect an abnormal substrate, RF current was applied at
the earliest activation site of induced VT or at the exit zone
detected on pace mapping.
The standard ablation setting of a non-irrigation catheter
consisted of a tip temperature of 60 1C and 30–40 W power for
4-mm tips or 40–50 W for 8-mm tips. When an irrigation catheter
was employed, a catheter tip temperature of 43 1C, a 35 W power,
and a 30 mL/min ﬂow rate were used.
At the end of the ablation procedure, VT induction was
performed with up to double extra stimuli and rapid pacing
(minimum pacing cycle at 240 ms, 15 beats) from the 2 sites.
Patients without induced VT were classiﬁed to the “No VT” group
and patients without induced clinical VT (documented on a 12-
lead ECG before ablation) were classiﬁed to the “No clinical VT”
group. In this study, the successful ablation (PCA success) group
was composed of the “No VT” and the “No clinical VT” groups.
Patients in whom clinical VT was induced at the end of the
procedure were classiﬁed to the “PCA failure” group.
2.3. Implantation of the cardioverter-deﬁbrillator
Implantation of the cardioverter-deﬁbrillator was performed
for all 101 patients. Patients in the ABL group received
cardioverter-deﬁbrillator implantation after catheter ablation.
The device programming consisted of a VF zone with a cut-off
rate of 200–220 beats per minute and a VT zone with a cut-off
cycle length of at least 40 ms above the cycle length of documen-
ted VT and anti-tachycardia pacing (ATP) followed by shock
therapy.
2.4. Follow-up
Patients were evaluated in outpatient clinics at 3-month inter-
vals. Analysis of VT recurrence depended on clearly differentiating
VT/VF events from supraventricular tachycardia events. For reli-
ably identifying VT, ICD diagnosis was conﬁrmed by two or more
physicians examining stored electrograms. VT recurrence was
deﬁned as appropriate ICD therapy, including shock and ATP. ES
was deﬁned as Z3 separate episodes of ventricular arrhythmia
during a 24-h period. Drug management during follow-up was
used at each physician's discretion.
2.5. Statistical analysis
Continuous variables are expressed as mean7standard devia-
tion; they were compared using two-sample t-tests. Categorical
variables were compared using the chi-squared test. Time-to-
event curves describing event-free survival of patients during
follow-up were calculated using the Kaplan–Meier method and
compared using the log-rank test. Statistical analyses were per-
formed using the SPSS statistical software program (version 20.0,
SPSS, Inc., Chicago, IL, USA). A two-sided po0.05 was considered
statistically signiﬁcant.
Fig. 1. Patient classiﬁcation. Prophylactic catheter ablation (PCA) was performed in
42 of 101 patients, classiﬁed as the ABL group. The remaining 59 patients were
classiﬁed as the No ABL group. Patients with no induced VT were classiﬁed as the
“No VT” group and patients with no induced clinical VT were classiﬁed as the “No
clinical VT” group. These two groups comprised the PCA success group. Patients in
which clinical VT was induced at the end of procedure were classiﬁed to the “PCA
failure” group.
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3. Results
3.1. Demographic and clinical characteristics
A total of 101 consecutive NICM patients with sustained VT
were retrospectively analyzed (66 men; mean age, 63.0712.2
years; mean left ventricular ejection fraction, 45.2714.2%; mean
left ventricular end-diastolic diameter [LVDd], 54.679.1 mm).
PCA was performed in 42 (41.6%) patients (ABL group). The remain-
ing 59 (58.4%) patients were classiﬁed as the No ABL group (Fig. 1).
There were no signiﬁcant group differences in demographic
or clinical characteristics, except for LVDd, number of documented
VT episodes before cardioverter-deﬁbrillator implantation, preva-
lence of dyslipidemia and ARVC (ABL group vs. No ABL group:
51.778.2 mm vs. 56.679.8 mm, p¼0.010; 2.2671.25 vs.
1.4970.84, po0.001; 5 of 42 [11.9%]) vs. 17 of 59 [40.5%],
p¼0.048; and 13 of 42 [31.0%] vs. 1 of 59 [1.7%], po0.001,
respectively) (Table 1).
3.2. Electrophysiological ﬁndings and catheter ablation data
The procedure was performed predominantly under local anesthe-
sia. A 4-mm tip non-irrigated ablation catheter was used in 31 (81.0%)
patients (Navistar; Biosense Webster in 29 patients; Ablaze Fantasista
4-mm distal tip; Japan Lifeline Co., Ltd., Tokyo, Japan in 5 patients);
a 4-mm and an 8-mm tip non-irrigated ablation catheter (Ablaze
Fantasista 8-mm distal tip; Japan Lifeline), in 3 patients; and a 3.5-mm
tip open-irrigated ablation catheter, in 8 (19.0%) patients (Navistar
Thermocool; Biosense Webster, in 5 patients; Coolpath Duo; St. Jude
Medical, St. Paul, MN, USA in 3 patients).
Electroanatomical mapping was performed using the CARTO
system in 37 (88.1%) patients and EnSite system was in 5 (11.9%).
An analysis of electroanatomical mapping in the endocardium
revealed the prevalence of a low voltage area or fractionated or
late potential as an arrhythmogenic substrate in 32 (76.2%) of 42
patients in the ABL group.
The mean number of induced VT morphology was 1.7 per
patient (range 0–5; 72 VTs). In 2 patients, a programmed stimula-
tion failed to induce VT. Clinically documented VT was induced in
39 patients. The underlying arrhythmia mechanism of 51 VTs was
presumed to be myocardial reentry on entrainment pacing and/or
activation mapping, recording mid-diastolic potential. The activa-
tion mapping of 11 VTs demonstrated a focal pattern. The
mechanism of the remaining 10 VTs was undetermined because
of hemodynamic instability, poor re-inducibility, or spontaneous
changes from one to another.
RF current was applied in 14 patients during 18 hemodynami-
cally tolerated VTs, which resulted in VT termination in 14 cases.
In 22 patients, RF current was applied for substrate modiﬁcation
during sinus rhythm. In 10 patients without low voltage areas or
fractionated or late potential as an arrhythmogenic substrate, RF
current was applied at the earliest activation site of induced VT or
at the exit zone detected on pace mapping.
After ablation, VT failed to be induced in 11 (26.2%) patients
(the “No VT” group) and clinical VT was not induced in 9 (21.4%)
patients (the “No clinical VT” group). RF ablation lesions were
created within the region identiﬁed to be abnormal by using
substrates and at the exit zone as detected on pace mapping in
2 patients in whom programmed stimulation failed to induce VT.
After substrate-based ablation eliminated abnormal potentials, VT
was not induced, and the patients were included in the No VT
group. These two groups were classiﬁed to the PCA success group.
In the remaining 22 patients (52.4%), endocardial catheter ablation
failed (the “PCA failure” group) (Fig. 1).
Epicardial mapping and ablation were not performed in any
patients at the index procedure. However, the arrhythmogenic
substrate of clinical VT was presumed to involve the epicardium in
20 patients, because the endocardial activation sequence did not
fulﬁll the cycle length of clinical VT or clinical VT was re-induced
after elimination of the endocardial arrhythmogenic substrate
(2 patients in the “No VT” group, 4 in the “No clinical VT” group,
and 14 in the “PCA failure” group). Fig. 2 shows a representative
case of successful endocardial PCA. This patient had cardiac sarcoi-
dosis and clinical hemodynamically unstable VT represented in the
left bundle branch block morphology with a cycle length of 320 ms.
The procedure was performed with the CARTO system navigation.
The substrate map of the RV and LV revealed an abnormal substrate
(an area with low amplitude [o1.5 mV]) in the RV and LV basal
septa (Fig. 2A–C). RF lesions were created to abolish the abnormal
substrate in the RV septum (white line in Fig. 2B). However, clinical
VT remained. The late potential during sinus rhythm was recorded
in the LV abnormal substrate (red star in Fig. 2A and D), and mid-
diastolic potential was recorded at this site during clinical VT
(Fig. 2E). RF application at this site terminated the VT (Fig. 2F),
and RF lesions were created from the mitral annulus to a normal
voltage area (41.5 mV) including the site (red line in Fig. 2C). No VT
was induced at the end of the procedure.
To determine in which patients endocardial PCA is most likely
to be successful, we analyzed differences in patients' baseline or
VT characteristics and in procedural details between successful
and unsuccessful PCA patients (Table 2). There were no differences
in baseline characteristics or underlying structural heart disease.
However, the PCA success group had higher rates of endocardial
substrate presence, and the PCA failure group had higher rates of
the presumption of epicardial substrate involvement and an
undetermined VT mechanism.
Table 1
Baseline demographic and clinical characteristics.
ABL group No ABL group p Value
(n¼42) (n¼59)
Mean follow-up duration (months) 41.5724.2 38.7723.6 0.567
Age (years) 60.4714.4 64.7710.7 0.083
Sex (male) 32 (76.2%) 34 (57.6%) 0.053
NYHA class I 9 (21.4%) 9 (15.3%) 0.424
NYHA class II 26 (61.9%) 34 (57.6%) 0.666
NYHA class III 7 (16.7%) 16 (27.1%) 0.217
NYHA class IV 0 0 NA
HTN 9 (21.4%) 19 (45.2%) 0.233
DM 5 (11.9%) 13 (31.0%) 0.19
DL 5 (11.9%) 17 (40.5%) 0.048
AF/AT 11 (26.2%) 24 (57.1%) 0.132
LVEF (%) 46.1712.7 44.5715.2 0.576
LVDd (mm) 51.778.2 56.679.8 0.01
Serum creatinine (mg/dl) 1.0670.95 1.2571.22 0.392
Amiodarone 7 (16.7%) 20 (47.6%) 0.054
Sotalol 13 (31.0%) 10 (16.9%) 0.098
β blocker 23 (54.8%) 40 (67.8%) 0.183
Number of VT episodes 2.2671.25 1.4970.84 o0.001
Cycle length of the clinical VT (ms) 326.4781.5 344.6774.7 0.248
Structural heart diseases
DCM 10 (23.8%) 22 (37.3%) 0.151
HCM 5 (11.9%) 13 (22.0%) 0.19
ARVC 13 (31.0%) 1 (1.7%) o0.001
Cardiac sarcoidosis 8 (19.0%) 10 (16.9%) 0.786
VHD 3 (7.1%) 7 (11.9%) 0.434
CHD 0 (0%) 3 (5.1%) 0.138
Others 3 (7.1%) 3 (5.1%) 0.666
AF/AT¼atrial ﬁbrillation/atrial tachycardia, ARVC¼arrhythmogenic right ventricu-
lar cardiomyopathy, CHD¼congenital heart disease, DCM¼dilated cardiomyopathy,
DL¼dyslipidemia, DM¼diabetes mellitus, HCM¼hypertrophic cardiomyopathy,
HTN¼hypertension, LVEF¼ left ventricular ejection fraction, LVDd¼ left ventricular
end-diastolic diameter, Number of VT episodes¼Number of VT episodes before
cardioverter-deﬁbrillator implantation, NYHA class¼New York Heart Association
classiﬁcation, VHD¼valvular heart disease, VT¼ventricular tachycardia.
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3.3. Complications
Periprocedural complications were observed in 2 (4.8%)
patients. One had an embolism in the superior mesenteric artery
with severe abdominal pain immediately after the procedure. The
other had a femoral hematoma at the puncture site, requiring
transfusion. Both patients fully recovered. No other major adverse
events were observed during the periprocedural period.
Fig. 2. A representative case of successful endocardial prophylactic catheter ablation. This patient had cardiac sarcoidosis and clinical hemodynamically unstable ventricular
tachycardia (VT). (A) Voltage map of the right ventricle (RV) and left ventricle (LV) in the right anterior oblique (RAO) view. The red star indicates where late potential during
sinus rhythm and mid-diastolic potential during clinical VT were recorded. Colors represent bipolar electrogram peak-to-peak amplitude, with purple being normal
(41.5 mV), and blue, green, yellow, and red regions with progressively lower amplitude. MA and TA indicate mitral annulus and tricuspid annulus, respectively. (B) Voltage
map of the RV in the left posterior oblique view. Low voltage area as an abnormal substrate existed in the lower basal-septum of RV. The white line indicates radiofrequency
(RF) lesions that were created to abolish the RV abnormal substrate. (C) Voltage map of LV in the RAO view. The red line indicates RF lesions that were created from the MA to
the normal voltage area, including the site of the red star in panel A. (D) Intra-cardiac electrogram during sinus rhythm at the site of the red star in panel A. The late potential
was recorded at this site. ABL indicates ablation catheter electrogram. HBE indicates His-bundle electrogram. RVd and RVp indicate RV distal and RV proximal bipolar
electrograms. (E) Intra-cardiac electrogram during clinical VT at the site of the red star in panel A. The mid-diastolic potential was recorded at this site. (F) Clinical VT
termination during RF application at the site of the red star in panel A.
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3.4. Long-term follow-up
During a follow-up period of 40.1723.9 months (range, 3–96
months, ABL group vs. No ABL group: 41.5724.2 vs. 38.7723.6
months, p¼0.567), VT recurrence, deﬁned as appropriate ICD
therapy after the index procedure, was found in 31 patients
(73.8%) in the ABL group and 48 (81.5%) in the No ABL group.
Twelve patients (28.6%) in the ABL group and 26 (44.1%) in the No
ABL group received an appropriate shock. In the Kaplan–Meier
analysis, there was no signiﬁcant difference between the ABL and
No ABL groups considering time to ﬁrst VT recurrence or shock
therapy during follow-up (p¼0.69, p¼0.21, respectively). Eleven
patients (26.2%) in the ABL group and 29 (49.2%) in the No ABL
group had ES. Kaplan–Meier analysis showed a signiﬁcant differ-
ence in time to ﬁrst ES between the ABL and No ABL groups
(p¼0.04) (Fig. 3A–C).
We divided the ABL group into the PCA success and the PCA
failure group and compared these groups with the No ABL group
(mean follow-up duration: PCA success group vs. No ABL group;
38.2721.1 vs. 38.7723.6 months, p¼0.920; the PCA success
group vs. the PCA failure group; 38.2721.1 vs. 44.5726.9 months,
p¼0.400). VT recurred in 11 patients (55.0%) in the PCA success
group and 20 (90.9%) in the PCA failure group. Two patients
(10.0%) in the PCA success group and 10 (45.5%) in the PCA failure
group received an appropriate shock. Two patients (10.0%) in the
PCA success group and 9 (40.9%) in the PCA failure group had ES.
By deﬁnition, patients in the PCA success group had a lower
incidence of ICD shocks and ES when compared with the No ABL
group. In the Kaplan–Meier analysis, the time to ﬁrst VT recur-
rence, shock therapy, and ES occurrence were signiﬁcantly longer
in the PCA success group than in the No ABL group (p¼0.02,
p¼0.01 and po0.01, respectively) (Fig. 4A–C).
At least 1 repeated catheter ablation was needed for ES in 4 of
42 patients (9.5%) in the ABL group (1 in the PCA success group
and 3 in the PCA failure group). Two patients required an
epicardial approach. Catheter ablation was needed for ES and/or
frequent ICD shock therapy in 6 of 59 patients (10.2%) in the No
ABL group. Two patients in the No any VT group had VT recurrence
at 43 years after PCA. In these cases, the cycle length of recurring
VTs (210 ms and 360 ms) was faster than those initially documen-
ted (260 ms and 400 ms).
All-cause death occurred in 1 patient (2.4%) in the ABL group
and in 13 (22.0%) in the No ABL group (po0.01). Death due to a
cardiovascular event occurred in 6 patients (1 patient [2.4%] in the
Table 2
Comparison of baseline demographic and clinical VT characteristics and procedural details between patients with successful PCA and those with unsuccessful PCA.
PCA success group PCA failure group p Value
(n¼20) (n¼22)
Baseline characteristics
Age (years) 62.3713.6 58.6715.2 0.424
Sex (male [%]) 15 (75.0%) 17 (77.3%) 0.863
NYHA class Z II (N [%]) 15 (75.0%) 18 (81.8%) 0.591
HTN 5 (25.0%) 4 (18.2%) 0.591
DL 1 (5.0%) 4 (18.2%) 0.188
DM 1 (5.0%) 4 (18.2%) 0.188
AT/AF 7 (35.0%) 4 (18.2%) 0.216
LVEF (%) 43.6713.9 48.5711.4 0.215
LVDd (mm) 53.577.8 50.178.5 0.186
Serum creatinine (mg/dl) 1.2171.34 0.9370.29 0.683
Structural heart disease
DCM 3 (15.0%) 7 (31.8%) 0.201
HCM 3 (15.0%) 2 (9.1%) 0.555
ARVC 7 (35.0%) 6 (27.3%) 0.588
Cardiac sarcoidosis 3 (15.0%) 5 (22.7%) 0.524
VHD 2 (10.0%) 1 (4.5%) 0.493
CHD 0 (0%) 0 (0%) NA
Others 2 (10.0%) 1 (4.5%) 0.493
Medication
Amiodarone 3 (15.0%) 4 (18.2%) 0.782
Sotalol 4 (20.0%) 9 (41.0%) 0.143
β blocker 13 (65.0%) 10 (45.5%) 0.204
Clinical VT characteristics
CL of the clinical VT 318.0758.2 334.1798.9 0.990
Number of VT episodes 2.1571.18 2.3671.33 0.653
RBBB type 12 (60.0%) 14 (63.6%) 0.808
Procedural ﬁndings
3-D navigation system (CARTO [%]) 17 (85.0%) 20 (90.9%) 0.555
Irrigated-tip ablation catheter usage 4 (20.0%) 4 (18.2%) 0.881
Number of induced VT 1.6071.19 (total 32 VTs) 1.8271.22 (total 40 VTs) 0.579
Myocardial re-entry 27 of 32 VTs 24 of 40 VTs 0.599
Focal activation pattern 5 of 32 VTs 6 of 40 VTs 0.869
Undetermined mechanism 0 of 32 VTs 10 of 40 VTs 0.007
Presence of endocardial substrate 18 (90.0%) 14 (63.6%) 0.045
VT termination during RF application 9 (45.0%) 5 (22.7%) 0.126
Presumption of epicardial substrate involvement 6 (30.0%) 14 (63.6%) 0.029
AF/AT¼atrial ﬁbrillation/atrial tachycardia, ARVC¼arrhythmogenic right ventricular cardiomyopathy, CHD¼congenital heart disease, CL¼cycle length, DCM¼dilated
cardiomyopathy, DL¼dyslipidemia, DM¼diabetes mellitus, HCM¼hypertrophic cardiomyopathy, HTN¼hypertension, LVEF¼ left ventricular ejection fraction, LVDd¼ left
ventricular end-diastolic diameter, RF¼radiofrequency, RBBB¼right bundle branch block, PCA¼prophylactic catheter ablation, Number of VT episodes¼Number of VT
episodes before cardioverter-deﬁbrillator implantation, VHD¼valvular heart disease, VT¼ventricular tachycardia.
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Fig. 3. Kaplan–Meier survival analysis comparing the ABL and no ABL groups.
(A) VT recurrence free survival. (B) ICD shock therapy free survival. (C) ES
occurrence free survival. The p value was calculated using the log-rank test.
Fig. 4. Kaplan–Meier survival analysis comparing the PCA success group, the PCA
failure group, and the No ABL group. (A) VT recurrence free survival. (B) ICD shock
therapy free survival. (C) ES occurrence free survival. The p value was calculated
using the log-rank test.
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ABL group and 5 [8.5%] in the No ABL group, p¼0.13). Causes of
non-cardiovascular death in 8 patients included cancer, infection,
and interstitial pneumonia.
4. Discussion
4.1. Major ﬁndings
Major ﬁndings of this retrospective cohort study are as follows:
(1) There were no signiﬁcant differences in VT recurrence or ICD
shock therapy between the ABL and No ABL groups. However,
there was a notable reduction in ES occurrence in the
ABL group.
(2) PCA success correlated with prolonging the time to VT
recurrence and shock therapy, ES. However, the success rate
was low (52.4%) although our procedural endpoint was not
failure to induce “any VT” but failure to induce “clinical VT.”
4.2. Comparison to previous studies, procedural endpoints and
clinical outcomes
Several studies have described long-term results of catheter
ablation for VT with different ablation strategies and procedural
endpoints in patients with structural heart diseases [4,5,12,14–16].
Catheter ablation performed to abolish all inducible VT in patients
with DCM has been reported to reduce mortality as well as VT
recurrence and ES [14,17]. Arya et al. reported that, during a
median follow-up of 23 months, 87.5% of patients with DCM and
ES who underwent complete VT elimination were alive compared
with 40% who were alive after partial success [14]. The study
population in Arya et al.'s report was limited to those with VT and
ES, and 30.8% of patients needed a second procedure with
endocardial and epicardial ablation. The rate of VT recurrence
was relatively high in our study, which may have been because
clinical outcomes were based on a single endocardial PCA proce-
dure. Clinical outcomes for cardiovascular death and all-cause
mortality were similar between our study and the previous study
although the procedural endpoint in our study was not the
inability to induce “any VT” but rather an inability to induce
“clinical VT.” PCA for clinical VT may modify the VT substrate and
strengthen ATP therapy's efﬁcacy, which might result in reduced
ICD shocks, ES, and mortality. This suggests that inability to induce
clinical VT may be an acceptable endpoint for prophylactic abla-
tion. However, our observed high rate of VT recurrence after a
single endocardial PCA procedure and low success rate are issues
to be resolved. These results indicate the need for additional
epicardial ablation. However, procedures using the epicardial
approach are still associated with a relatively high rate of compli-
cations, periprocedural mortality, and difﬁculty during repeat
procedures because of epicardial adhesions [8,15,18], all of which
make us hesitant to employ epicardial ablation as a prophylactic
therapy before cardioverter-deﬁbrillator implantations.
4.3. Arrhythmogenic substrate and patient selection
In our study, prophylactic endocardial ablation for targeted
clinical VT failed in 22 (52.4%) of 42 patients. Elimination of all
inducible VTs is difﬁcult in patients with NICM because the
arrhythmogenic substrate may frequently include an epicardial
scar [19–22]. Bogun et al. reported that delayed-enhancement
magnetic resonance imaging (DE–MRI) could identify the location
of the VT substrate in 3 dimensions and that only 36% of patients
with NICM had a predominant endocardial scar [19]. In our study,
an analysis of electroanatomical mapping revealed the prevalence
of arrhythmogenic substrates in the endocardium in 76.2% of
patients in the ABL group. This discrepancy might be explained
by the different assessment modalities used. In our cases, both an
endocardial and an epicardial substrate might exist, while in the
study by Bogun et al., DE-MRI might have underestimated the
endocardial scar. Recently, Bala et al. investigated whether intra-
cardiac echocardiography (ICE) imaging could identify abnormal
epicardial substrates in patients with NICM and VT. In their study,
the epicardial scar identiﬁed by electroanatomical mapping corre-
lated with the echogenic area identiﬁed on ICE imaging [23].
Therefore, modern technologies, such as DE-MRI and ICE imaging,
facilitate improvements in substrate-speciﬁc strategies and help
guide decision-making regarding utilization of the endocardial
and/or epicardial approach.
4.4. Role of PCA and mechanisms of VT recurrence
Our study suggests that PCA with non-inducible clinical VT can
provide a long-lasting reduction in VT recurrence and ES, particu-
larly within the ﬁrst 3 years after the procedure. The re-entry
circuit of clinical VT appears to be important for maintaining
spontaneously occurring VT, and modifying the re-entry circuit
might suppress VT occurrence or make it more vulnerable to
termination. We speculate that those VT recurrences result from
the formation of new arrhythmogenic substrates.
4.5. Study limitations
First, this study involved a relatively small sample size. Second,
our ﬁndings are based on a retrospective analysis. In this study,
patients were not randomly assigned to therapeutic strategies (i.e.,
with or without PCA), and various antiarrhythmic drugs were
used, which could lead to biases in the occurrence of endpoints.
Third, this study had a heterogeneous population, including
patients with various non-ischemic structural heart diseases. The
clinical condition of ARVC patients is different from other non-
ischemic diseases and may have affected our results. However,
one-third of them had reduced LV function, indicating ARVC
progression involving LV myocardium, and the underlying struc-
tural heart diseases did not differ between the ABL success and the
ABL unsuccess groups. Finally, “non-irrigated” tip ablation cathe-
ters were used in the majority of patients (81.0%) because irrigated
catheters were unavailable in Japan during most of the study
period. Use of an irrigated catheter may improve outcomes.
Further prospective, randomized controlled studies are required
to clarify this issue.
5. Conclusions
Prophylactic endocardial catheter ablation can decrease ES
occurrence in NICM patients. However, our high rate of VT
recurrence and low success rate are issues to be resolved, and
the efﬁcacy of a single endocardial catheter ablation was limited.
These results indicate the need for additional epicardial ablation.
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